

Supplementary Figure 1. DX126-262 demonstrated superior *in vivo* antitumor activity when compared to the single drug or combination of antibody and payload. A. *In vivo* antitumor efficacy of DX126-262 (ADC), DX-CHO9 (mAb), Tub-114-cys (payload), and DX-CHO9 combined with Tub-114-cys were evaluated in NCI-N87 xenograft model. The tumor-bearing mice were intravenously administered with DX126-262 (8 mg/kg), DX-CHO9 (8 mg/kg), Tub-114-cys (equal molar concentration with DX126-262) or the combination of DX-CHO9 and Tub-114-cys. The arrow indicates the date of a single intravenous administration. Each point represents the Mean tumor volume and SD (n=10). ****P<0.0001. B. Tumor weights of NCI-N87 xenografts were represented as Mean ± SD. ns: no significance, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.